In this article, Michael Avraam, global product manager at ChargePoint Technology discusses the potential issues with containment performance testing, the data collection methods and how the results are interpreted, as well as the impact this may have on the end user. He also describes some techniques and developments that may help to ensure efficient containment performance testing.
chemicals
Growing demand for high potency active pharmaceutical ingredients (HPAPI) and the rising prevalence of specific therapy areas, such as oncology, immune-suppressants and hormone, are fuelling the need for high potency handling capabilities. As the use of high potency containment systems is rising, manufacturers are looking at more innovative containment strategies and containment verification has never been so important. However, it’s critical to understand the variations in testing and the challenges posed by potential differences in the interpretation of results.